Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

Inclusion criteria

• Healthy adult male subjects meeting all the criteria below or adult male subjects having no obvious disease other than high cholesterol levels.
• Aged 20 years or over and 65 years or below when the informed consent is obtained.
• Weighing 50 kg or over and 80 kg or below on the day of the screening tests, with BMI [Body Mass Index: body weight (kg)/height (m)2] ranging from 16.5 to 27.5.

Exclusion criteria

Patients meeting any one of the following conditions are excluded from the study.

• Subjects with the triglyceride value at screening test exceeding 500 mg/dL.
• Subjects with past history of drug allergy (shock, anaphylactic symptom, and angioedema).
• Subjects with past history of alcohol or drug dependence.
• Subjects with past history of mental disorder.
• Subjects positive in the test for HBs antigen, HCV antibody, or HIV antibody or in the serological test for syphilis.
• Subjects who used any drug within 2 weeks of investigational product administration in Period 1.
• Subjects who have drawn more than 400 mL of blood within 12 weeks before administration day in Period 1.
• Subjects who participated in other study within 16 weeks of investigational product administration in Period 1 and was administered a investigational product.
• Subjects who cannot take contraceptive measures during the study period (from providing informed consent to completion of Period 3 examination)
• Subjects who the investigator judges are inappropriate to participate in the study.